Meiyu Wu

620 total citations
27 papers, 479 citations indexed

About

Meiyu Wu is a scholar working on Materials Chemistry, Surgery and Biomedical Engineering. According to data from OpenAlex, Meiyu Wu has authored 27 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Materials Chemistry, 5 papers in Surgery and 5 papers in Biomedical Engineering. Recurrent topics in Meiyu Wu's work include Nanoparticles: synthesis and applications (6 papers), Graphene and Nanomaterials Applications (4 papers) and Fibroblast Growth Factor Research (3 papers). Meiyu Wu is often cited by papers focused on Nanoparticles: synthesis and applications (6 papers), Graphene and Nanomaterials Applications (4 papers) and Fibroblast Growth Factor Research (3 papers). Meiyu Wu collaborates with scholars based in China, United Kingdom and Kazakhstan. Meiyu Wu's co-authors include Liming Xie, Ying Liu, Lin Liu, Hongbo Guo, Liang Chen, Liming Xu, Chun‐Hsing Liao, Xiaomin Wan, Chongqing Tan and Shan Jiang and has published in prestigious journals such as Applied Microbiology and Biotechnology, Frontiers in Immunology and European Journal of Immunology.

In The Last Decade

Meiyu Wu

26 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Meiyu Wu China 10 167 118 109 97 37 27 479
Sujing Qiang China 8 80 0.5× 142 1.2× 162 1.5× 87 0.9× 26 0.7× 12 461
Andrew J. Ditto United States 10 152 0.9× 182 1.5× 94 0.9× 90 0.9× 19 0.5× 14 604
Hyeongseop Keum South Korea 12 86 0.5× 189 1.6× 125 1.1× 97 1.0× 17 0.5× 27 573
Xiaojing Chen China 14 89 0.5× 172 1.5× 170 1.6× 107 1.1× 14 0.4× 35 716
Tongfei Shi China 10 81 0.5× 156 1.3× 119 1.1× 96 1.0× 12 0.3× 12 513
Roghayyeh Vakili‐Ghartavol Iran 10 91 0.5× 149 1.3× 177 1.6× 173 1.8× 20 0.5× 21 505
Wenting Chen China 14 58 0.3× 182 1.5× 86 0.8× 133 1.4× 56 1.5× 41 648
Teodora Pop Romania 13 170 1.0× 169 1.4× 297 2.7× 81 0.8× 17 0.5× 27 591
Huiqun Hu China 13 96 0.6× 213 1.8× 220 2.0× 109 1.1× 49 1.3× 24 641
Jianati Dawulieti China 10 86 0.5× 281 2.4× 239 2.2× 168 1.7× 21 0.6× 11 731

Countries citing papers authored by Meiyu Wu

Since Specialization
Citations

This map shows the geographic impact of Meiyu Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meiyu Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meiyu Wu more than expected).

Fields of papers citing papers by Meiyu Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meiyu Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meiyu Wu. The network helps show where Meiyu Wu may publish in the future.

Co-authorship network of co-authors of Meiyu Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Meiyu Wu. A scholar is included among the top collaborators of Meiyu Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meiyu Wu. Meiyu Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Xuexue, Weiyuan Huang, Yi Zhao, et al.. (2025). Application and Safety Research of Nanotechnology in Cosmetics: Current Status, Challenges, and Future Prospects. BioNanoScience. 15(2). 3 indexed citations
2.
Pan, Xuexue, Zhenchen Zhong, Xiaoxiao Hu, et al.. (2025). Application of nanotechnology in anti-aging cosmetics: advantages, challenges, and prospects. Polymer Bulletin. 82(14). 8635–8725.
3.
Wang, Siying, et al.. (2024). Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research. 25(2). 173–178. 2 indexed citations
4.
Li, Andong, et al.. (2024). Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States. Frontiers in Immunology. 15. 1464092–1464092. 4 indexed citations
5.
6.
Wu, Meiyu, Lu Wang, Haijing Wu, et al.. (2023). Leptin deficiency in CD8+ T cells ameliorates non-segmental vitiligo by reducing interferon-γ and Granzyme B. Frontiers in Immunology. 14. 1158883–1158883. 7 indexed citations
7.
Wu, Meiyu, Wenjing Pan, Jia Chen, et al.. (2022). Systemic lupus erythematosus patients contain B‐cell receptor repertoires sensitive to immunosuppressive drugs. European Journal of Immunology. 52(4). 669–680. 9 indexed citations
8.
Wang, Xuehong, Sini Li, Chongqing Tan, et al.. (2022). Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study. PharmacoEconomics. 40(7). 725–737. 9 indexed citations
9.
Duan, Lili, et al.. (2022). Effect of resveratrol on endocrine function, oocyte oxidation and apoptosis in mice with polycystic ovary syndrome. Tropical Journal of Pharmaceutical Research. 20(5). 1009–1015. 2 indexed citations
10.
Wang, Xuehong, Sini Li, Chongqing Tan, et al.. (2022). Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study. Frontiers in Public Health. 10. 955120–955120. 8 indexed citations
11.
Wu, Meiyu, Liting Wang, Chongqing Tan, et al.. (2022). Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review. Frontiers in Pharmacology. 13. 860109–860109. 13 indexed citations
12.
Wu, Meiyu, Ming Zhao, Haijing Wu, & Qianjin Lu. (2021). Immune repertoire: Revealing the “real-time” adaptive immune response in autoimmune diseases. Autoimmunity. 54(2). 61–75. 5 indexed citations
13.
Wu, Meiyu, Hongbo Guo, Lin Liu, Ying Liu, & Liming Xie. (2019). <p>Size-dependent cellular uptake and localization profiles of silver nanoparticles</p>. International Journal of Nanomedicine. Volume 14. 4247–4259. 221 indexed citations
14.
Chen, Liang, Meiyu Wu, Shan Jiang, et al.. (2019). <p>Skin Toxicity Assessment of Silver Nanoparticles in a 3D Epidermal Model Compared to 2D Keratinocytes</p>. International Journal of Nanomedicine. Volume 14. 9707–9719. 56 indexed citations
15.
Wu, Meiyu, Na Song, Zhao Yang, et al.. (2017). Increased production of human fibroblast growth factor 17 in Escherichia coli and proliferative activity in NIH3T3 cells. Molecular Medicine Reports. 16(1). 447–452. 1 indexed citations
16.
Tian, Haishan, Zhao Yang, Meiyu Wu, et al.. (2015). High production in E. coli of biologically active recombinant human fibroblast growth factor 20 and its neuroprotective effects. Applied Microbiology and Biotechnology. 100(7). 3023–3034. 12 indexed citations
17.
Li, Suping, Yanhua Tian, Ying Zhao, et al.. (2015). pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growth. Oncotarget. 6(27). 23523–23532. 30 indexed citations
18.
Hsu, Meng-Shiuan, et al.. (2013). Haemophilus parainfluenzae urethritis among homosexual men. Journal of Microbiology Immunology and Infection. 48(4). 450–452. 19 indexed citations
19.
Wu, Meiyu, et al.. (2012). WSN-based Health Care Management Platform for Long-Term Care Institutions. Journal of Convergence Information Technology. 7(7). 303–311. 5 indexed citations
20.
Liao, Chun‐Hsing, Chih‐Cheng Lai, Fang‐Yeh Chu, et al.. (2010). Antimicrobial susceptibility of Neisseria gonorrhoeae isolates determined by the agar dilution, disk diffusion and Etest methods: comparison of results using GC agar and chocolate agar. International Journal of Antimicrobial Agents. 35(5). 457–460. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026